Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Colorectal cancer in younger patients isn't just more common — it's biologically different. A landmark study published in Nature Medicine analyzed over 850,000 cancer cells from 189 tumors and found that tumors in patients under 50 have a higher proportion of connective tissue cells (linked to chemo resistance) and more active long non-coding RNAs. The findings could open new doors for targeted prevention and treatment strategies.
Colorectal cancer is rising fast among younger adults, and now researchers think they know part of why it hits harder. A major new study from Dana-Farber Cancer Institute, Mass General Brigham, and the Broad Institute — published in Nature Medicine — reveals that colorectal tumors in patients under 50 are biologically distinct from those in older patients, not just clinically different.
Using single-nucleus RNA sequencing on archived tumor samples, the team mapped gene activity across more than 850,000 cells from 189 tumors spanning patients aged 29 to 90+. Rather than a simple young-vs.-old comparison, they tracked how tumor biology shifts gradually with age — a more nuanced approach that uncovered patterns previous studies missed.
Key Takeaways:
Why it matters: Colorectal cancer is now the leading cause of cancer death in Americans under 50, with diagnosis rates climbing nearly 3% per year. These biological insights lay the groundwork for developing age-specific prevention strategies, diagnostic tools, and targeted therapies — a critical step toward closing the gap for younger patients who are often diagnosed at more advanced stages.
